Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

NCT03217097 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT03217097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03217097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Lead sponsor
Hospices Civils de Lyon
Phase
Not applicable
Overall status
Completed
Start date
October 16, 2018
Completion date
April 25, 2022
Enrollment
116 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors